NZ613167A - Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds - Google Patents
Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compoundsInfo
- Publication number
- NZ613167A NZ613167A NZ613167A NZ61316711A NZ613167A NZ 613167 A NZ613167 A NZ 613167A NZ 613167 A NZ613167 A NZ 613167A NZ 61316711 A NZ61316711 A NZ 61316711A NZ 613167 A NZ613167 A NZ 613167A
- Authority
- NZ
- New Zealand
- Prior art keywords
- azole
- treatment
- parenteral administration
- solvent
- preparing
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000007911 parenteral administration Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003851 azoles Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 abstract 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 abstract 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 abstract 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 abstract 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 abstract 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 abstract 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 abstract 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 abstract 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 abstract 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- TYBHXIFFPVFXQW-UHFFFAOYSA-N abafungin Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1=CSC(NC=2NCCCN=2)=N1 TYBHXIFFPVFXQW-UHFFFAOYSA-N 0.000 abstract 1
- 229950006373 abafungin Drugs 0.000 abstract 1
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- 229960002206 bifonazole Drugs 0.000 abstract 1
- 229960005074 butoconazole Drugs 0.000 abstract 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004022 clotrimazole Drugs 0.000 abstract 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 abstract 1
- 229960003913 econazole Drugs 0.000 abstract 1
- 229960001274 fenticonazole Drugs 0.000 abstract 1
- 229960004884 fluconazole Drugs 0.000 abstract 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- DDFOUSQFMYRUQK-RCDICMHDSA-N isavuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC=C(F)C=2)F)=NC=1C1=CC=C(C#N)C=C1 DDFOUSQFMYRUQK-RCDICMHDSA-N 0.000 abstract 1
- 229960000788 isavuconazole Drugs 0.000 abstract 1
- 229960004849 isoconazole Drugs 0.000 abstract 1
- 229960004130 itraconazole Drugs 0.000 abstract 1
- 229960004125 ketoconazole Drugs 0.000 abstract 1
- 229960002509 miconazole Drugs 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 229960004031 omoconazole Drugs 0.000 abstract 1
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 abstract 1
- 229960003483 oxiconazole Drugs 0.000 abstract 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 229960001589 posaconazole Drugs 0.000 abstract 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 abstract 1
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 abstract 1
- 229950004154 ravuconazole Drugs 0.000 abstract 1
- 229960005429 sertaconazole Drugs 0.000 abstract 1
- 229960002607 sulconazole Drugs 0.000 abstract 1
- 229960000580 terconazole Drugs 0.000 abstract 1
- 229960004214 tioconazole Drugs 0.000 abstract 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 abstract 1
- 229960004740 voriconazole Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42393710P | 2010-12-16 | 2010-12-16 | |
| US201161509154P | 2011-07-19 | 2011-07-19 | |
| PCT/US2011/065422 WO2012083138A2 (en) | 2010-12-16 | 2011-12-16 | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ613167A true NZ613167A (en) | 2015-09-25 |
Family
ID=46245384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ613167A NZ613167A (en) | 2010-12-16 | 2011-12-16 | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10307418B2 (enExample) |
| EP (1) | EP2651450B1 (enExample) |
| JP (2) | JP6086539B2 (enExample) |
| CN (1) | CN103402543B (enExample) |
| AU (1) | AU2011343576B2 (enExample) |
| BR (1) | BR112013015085A8 (enExample) |
| CA (1) | CA2821823C (enExample) |
| DK (1) | DK2651450T3 (enExample) |
| ES (1) | ES2565353T3 (enExample) |
| HU (1) | HUE028667T2 (enExample) |
| IL (1) | IL226977A (enExample) |
| MX (1) | MX337364B (enExample) |
| NZ (1) | NZ613167A (enExample) |
| RU (2) | RU2618456C2 (enExample) |
| WO (1) | WO2012083138A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2565353T3 (es) * | 2010-12-16 | 2016-04-04 | Borje S. Andersson | Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol |
| DK2701684T3 (en) * | 2011-04-28 | 2017-09-18 | Platform Brightworks Two Ltd | Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use |
| MX2015003579A (es) * | 2012-12-28 | 2015-06-22 | Suntory Holdings Ltd | Bebida no alcoholica con sabor de cerveza, que tiene estabilidad en el sabor. |
| CN105394045B (zh) * | 2014-09-04 | 2020-02-14 | 中国科学院上海巴斯德研究所 | 一种肠道病毒的小分子化合物抑制剂及其应用 |
| CN105943500B (zh) * | 2016-07-08 | 2019-01-04 | 河南省立眼科医院 | 一种含有艾沙康唑的眼用纳米胶束抗真菌溶液 |
| TWI834808B (zh) * | 2019-02-19 | 2024-03-11 | 西班牙商薩爾瓦特實驗室有限公司 | 以單劑包裝的克氯黴唑液體組成物 |
| CN111665301A (zh) * | 2020-05-29 | 2020-09-15 | 南京品生医疗科技有限公司 | 超高效液相色谱串联质谱技术检测血清中抗真菌药物的试剂盒 |
| JP2023549542A (ja) * | 2020-11-16 | 2023-11-27 | ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド | 曇点の無い製剤、方法及び予充填複数回投与注入機器 |
| CN113671086B (zh) * | 2021-08-31 | 2023-06-16 | 重庆华邦制药有限公司 | 分离、测定泊沙康唑z2及其杂质的方法 |
| CN114660200A (zh) * | 2022-03-29 | 2022-06-24 | 中国人民解放军总医院 | 一种高效液相色谱串联质谱技术同时测定血浆中4种三唑类抗真菌药物的方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912124A (en) * | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
| DE3702105A1 (de) | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| JPH01242525A (ja) | 1988-03-25 | 1989-09-27 | Nippon Nohyaku Co Ltd | 抗真菌外用剤 |
| PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| PH31594A (en) * | 1993-09-30 | 1998-11-03 | Janssen Pharmaceutica Nv | Oral formulations on an antifungal. |
| KR0159730B1 (ko) * | 1996-01-15 | 1998-12-01 | 손경식 | 케토코나졸 수성 제제 |
| US7179475B1 (en) * | 1998-12-04 | 2007-02-20 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
| US6362172B2 (en) * | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
| GB2365770B (en) * | 2000-08-18 | 2002-07-31 | Diomed Dev Ltd | Antifungal ketoconazole composition for topical use |
| US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| JP2002322056A (ja) * | 2001-04-27 | 2002-11-08 | Nippon Kayaku Co Ltd | トリアゾール誘導体の溶液製剤 |
| JP4263441B2 (ja) * | 2002-08-07 | 2009-05-13 | 富士重工業株式会社 | ４輪駆動車の制御装置 |
| AU2003249510A1 (en) * | 2002-08-12 | 2004-02-25 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
| ZA200409537B (en) | 2003-01-31 | 2006-10-25 | Yamanouchi Pharma Co Ltd | Stable solid medicinal composition for oral administration |
| US20060003654A1 (en) * | 2004-06-30 | 2006-01-05 | Lostocco Michael R | Dispersible alcohol/cleaning wipes via topical or wet-end application of acrylamide or vinylamide/amine polymers |
| JP2008534610A (ja) * | 2005-03-31 | 2008-08-28 | ブリストル−マイヤーズ スクイブ カンパニー | イクサベピロンの投与方法 |
| EP1895843A4 (en) * | 2005-06-27 | 2010-06-02 | Stiefel Laboratories | TOPICAL MICOGEL FORMULATIONS |
| US20070082870A1 (en) * | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| EP2097065A2 (en) * | 2006-11-29 | 2009-09-09 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
| JP5529539B2 (ja) | 2007-09-05 | 2014-06-25 | 株式会社ポーラファルマ | 医薬組成物 |
| US20090253712A1 (en) * | 2008-04-03 | 2009-10-08 | Semmelweis Egyetem | Aqueous solvent system for solubilization of azole compounds |
| US20090286799A1 (en) * | 2008-05-16 | 2009-11-19 | Zhi-Gang Jiang | Methods for the treatment of brain edema |
| KR20110128283A (ko) | 2009-02-05 | 2011-11-29 | 타겟티드 딜리버리 테크놀러지스 리미티드 | 미생물체의 증식 및 생존도를 감소시키는 방법 |
| EP2416757A2 (en) * | 2009-04-09 | 2012-02-15 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| ES2565353T3 (es) * | 2010-12-16 | 2016-04-04 | Borje S. Andersson | Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol |
| DK2701684T3 (en) * | 2011-04-28 | 2017-09-18 | Platform Brightworks Two Ltd | Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use |
-
2011
- 2011-12-16 ES ES11849408.7T patent/ES2565353T3/es active Active
- 2011-12-16 NZ NZ613167A patent/NZ613167A/en not_active IP Right Cessation
- 2011-12-16 HU HUE11849408A patent/HUE028667T2/en unknown
- 2011-12-16 MX MX2013006816A patent/MX337364B/es active IP Right Grant
- 2011-12-16 US US13/994,152 patent/US10307418B2/en active Active
- 2011-12-16 JP JP2013544816A patent/JP6086539B2/ja not_active Expired - Fee Related
- 2011-12-16 WO PCT/US2011/065422 patent/WO2012083138A2/en not_active Ceased
- 2011-12-16 AU AU2011343576A patent/AU2011343576B2/en not_active Ceased
- 2011-12-16 CA CA2821823A patent/CA2821823C/en not_active Expired - Fee Related
- 2011-12-16 BR BR112013015085A patent/BR112013015085A8/pt active Search and Examination
- 2011-12-16 RU RU2013132703A patent/RU2618456C2/ru not_active IP Right Cessation
- 2011-12-16 DK DK11849408.7T patent/DK2651450T3/en active
- 2011-12-16 RU RU2016149770A patent/RU2734128C2/ru active
- 2011-12-16 CN CN201180067824.5A patent/CN103402543B/zh not_active Expired - Fee Related
- 2011-12-16 EP EP11849408.7A patent/EP2651450B1/en not_active Not-in-force
-
2013
- 2013-06-16 IL IL226977A patent/IL226977A/en active IP Right Grant
-
2017
- 2017-01-27 JP JP2017013634A patent/JP6529527B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-16 US US16/385,293 patent/US20190240216A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012083138A3 (en) | 2012-11-01 |
| RU2618456C2 (ru) | 2017-05-03 |
| RU2016149770A3 (enExample) | 2020-02-04 |
| BR112013015085A2 (pt) | 2016-08-09 |
| US20190240216A1 (en) | 2019-08-08 |
| US10307418B2 (en) | 2019-06-04 |
| CN103402543B (zh) | 2015-09-16 |
| JP6086539B2 (ja) | 2017-03-01 |
| ES2565353T3 (es) | 2016-04-04 |
| JP2013545819A (ja) | 2013-12-26 |
| CA2821823C (en) | 2019-05-07 |
| BR112013015085A8 (pt) | 2018-04-03 |
| MX337364B (es) | 2016-02-29 |
| WO2012083138A2 (en) | 2012-06-21 |
| IL226977A (en) | 2017-01-31 |
| MX2013006816A (es) | 2013-11-01 |
| JP2017114869A (ja) | 2017-06-29 |
| RU2734128C2 (ru) | 2020-10-13 |
| CA2821823A1 (en) | 2012-06-21 |
| HUE028667T2 (en) | 2016-12-28 |
| HK1190643A1 (zh) | 2014-07-11 |
| EP2651450B1 (en) | 2015-12-16 |
| JP6529527B2 (ja) | 2019-06-12 |
| AU2011343576B2 (en) | 2016-09-08 |
| CN103402543A (zh) | 2013-11-20 |
| EP2651450A2 (en) | 2013-10-23 |
| RU2013132703A (ru) | 2015-01-27 |
| EP2651450A4 (en) | 2014-07-09 |
| AU2011343576A1 (en) | 2013-07-11 |
| RU2016149770A (ru) | 2018-11-05 |
| US20140031366A1 (en) | 2014-01-30 |
| DK2651450T3 (en) | 2016-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ613167A (en) | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds | |
| JP2011500779A5 (enExample) | ||
| JP2021054849A (ja) | Ｃ型肝炎を治療するための方法 | |
| JP2013545819A5 (enExample) | ||
| AR128189A2 (es) | Combinaciones fungicidas | |
| JP2017536371A5 (enExample) | ||
| ES2981685T3 (es) | Utilización de pimobendán para la reducción del tamaño cardíaco y el retraso de la aparición de los síntomas clínicos en pacientes con insuficiencia cardíaca asintomática debido a enfermedad valvular mitral | |
| RU2017121370A (ru) | Противогрибковые агенты | |
| JP2012509327A5 (enExample) | ||
| MX368157B (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. | |
| KR20150028241A (ko) | 약학적 조성물 | |
| CN104661662A (zh) | 治疗丙型肝炎的方法 | |
| RU2006129637A (ru) | Вагинальные композиции для лечения инфекций | |
| PH12017501831A1 (en) | Pharmaceutical compositions for oral administration | |
| JP2015528513A (ja) | Ｃ型肝炎を治療するための方法 | |
| HRP20250042T1 (hr) | Polimorfi triazolnog antifungalnog spoja pc945 | |
| NZ591741A (en) | Benzimidazole anthelmintic compositions | |
| NZ603414A (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof | |
| US20100273834A1 (en) | Treatment of onychomycosis and related compositions including urea | |
| WO2007145563A8 (en) | Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor | |
| AU2014301961B2 (en) | Antimicrobial compositions and methods of use | |
| US20100261695A1 (en) | Treatment of onychomycosis and related compositions | |
| HK40021071A (en) | Methods for treating hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ANDERSSON, US Effective date: 20151119 Owner name: TARRAND JEFFREY, US Effective date: 20151119 Owner name: VALDEZ, US Effective date: 20151119 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 DEC 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20160407 |
|
| ASS | Change of ownership |
Owner name: PLATFORM BRIGHTWORKS TWO, LTD, US Effective date: 20170223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 DEC 2019 BY CPA GLOBAL Effective date: 20181213 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 DEC 2020 BY CPA GLOBAL Effective date: 20191031 |
|
| LAPS | Patent lapsed |